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One potential reason for avoiding strat-
egies that have mixed cardioplegia and sys-
temic perfusion temperatures (cold for one
with warm or tepid for the other) is the
concern that the myocardial temperature in
the mixed temperatures situation would
likely result in highly variable and incon-
sistent myocardial temperatures.1 It has
been demonstrated that the delivery of cold
cardioplegia results in decreased subepicar-
dial and midwall ventricular perfusion.
This datum, coupled with information that
myocardial temperature is variable with
cold cardioplegia, suggests that myocardial
protection may be compromised by such a
mixed temperature environment.2
However, others have shown no in-
crease in the release of myocardial injury
markers (troponin I and T) after normother-
mic systemic perfusion relative to hypo-
thermic systemic perfusion when a regimen
of cold cardioplegia with topical cooling
was used for myocardial protection, and
acceptable clinical results are possible.3
Furthermore, acceptable clinical results
have been reported with the technique of
cold cardioplegia with warm systemic per-
fusion.4 Thus considerable controversy
continues to exist regarding whether cold
cardioplegia with warm systemic perfusion
is harmful; however, there are no studies
demonstrating its superiority to the strategy
of warm cardioplegia with tepid systemic
perfusion.
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Nickel allergy to the percutaneous
patent foramen ovale occluder and
subsequent systemic nickel allergy
To the Editor:
We read with great interest the article
“Systemic Allergic Reaction to the Per-
cutaneous Patent Foramen Ovale Oc-
cluder” by Fukahara and colleagues.1 In
that article, Fukahara and colleagues1 de-
scribed the case of a 37-year-old patient
who underwent patent foramen ovale clo-
sure with the Star device (Cardia Inc,
Burnsville, Minn). In the following 2
months, the patient began demonstrating
hypersensitivity to the device, confirmed
by skin patch testing as an allergy to
nitinol. Removal of the device ultimately
led to this patient’s recovery.
In October 2001, we treated an 11-year-
old boy who had undergone transcatheter
closure of a secundum type atrial septal
defect with the HELEX Septal Occluder
(W.L. Gore and Associates, Flagstaff,
Ariz).2 Similar to Fukahara and colleagues’
patient, our patient had a similar reaction to
the device; he ultimately had positive skin
patch test results for nickel allergy. This
patient underwent uneventful removal of
the device as well but also required subse-
quent removal of the sternal wires, which
had trace amounts of nickel. This patient
was initially unavailable for follow-up at
our institution. To our knowledge, how-
ever, he has had an otherwise uneventful
recovery.
We thank Fukahara and colleagues1 for
their report on the subject. We encourage
the cardiothoracic community at large to
report such events to determine objectively
the incidence of adverse outcomes that may
be associated with these emerging technol-
ogies.
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Activated prothrombin complex
concentrates and recombinant factor
VIIa in the bleeding patient: Are they
appropriate and safe?
To the Editor:
I read with great interest the article of Bui
and colleagues,1 “Fatal Thrombosis After
Administration of Activated Prothrombin
Complex Concentrates in a Patient Sup-
ported by Extracorporeal Membrane Ox-
ygenation Who Had Received Activated
Recombinant Factor VII,” in the October
2002 Journal. Many issues related to the
administration of activated prothrombin
complex concentrates presented by this
case were too simply discussed.
First, the patient had evidence of dis-
seminated intravascular coagulation both
before the cessation of heparin and after its
discontinuation, with prolonged prothrom-
bin time and partial thromboplastin time.
No data are available regarding the pa-
tient’s platelet count before or after surgi-
cal intervention. Both recombinant factor
VIIa and factor VIII bypassing activity
(FEIBA) were used off-label, about which
the authors made little comment. Cardiac
surgery with extracorporeal membrane ox-
ygenation is known to activate clotting, and
death might well have occurred even with-
out either biologic agent. The cardiac death
may not have been from thrombus, but of
another origin; because no autopsy was
performed, however, all this is pure spec-
ulation.
The authors stated with great conviction
that thrombosis with recombinant factor
VIIa is less common than with FEIBA.
Continued hemorrhage itself is a cause of
activation of coagulation. Agents known to
aid in stopping hemorrhage in patients with
coagulation defects have caused throm-
botic episodes.
Almost all the life-threatening throm-
botic events with FEIBA have occurred
with doses exceeding those recommend-
ed.2 Bui and colleagues1 provided no data
regarding the dose of FEIBA given.
Thrombotic events, including myocardial
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infarctions, have also been reported for re-
combinant factor VIIa.3 The relative risks
of these two biologic agents are unknown;
there are no prospective comparative data
available to make such a determination.
The cumulative clinical anecdotal data for
recombinant factor VIIa are from a much
briefer span than those for FEIBA.
Case reports can at times be important for
recognition of new diseases and during
postlicensing surveillance for adverse events.
Recently, a report has demonstrated that the
combination of recombinant factor VIIa and
FEIBA may, if anything, be additive without
increasing adverse responses.4,5
I caution the authors that conclusions
presented with inadequate data may well
lead readers to incorrect interpretations of
the events described.
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A few critical aspects—and Achilles
heels— of tissue engineering
approaches to restore injured
myocardium
To the Editor:
We enjoyed reading Osawa and col-
leagues’ article about histologic changes of
biomaterials used to repair ventricular heart
defects in small animals1 as published in
this Journal and also have followed this
group’s work elsewhere.2 Our own review
on the current literature in this area has
spawned many questions and suggestions
for future study designs.
Most published studies do not present
clinically applicable, reparative options.
We believe that a critical analysis of these
studies with respect to geometry, physiol-
ogy, and inflammatory and immunologic
responsiveness of myocardium will help
identify flaws in current study designs and
also help define standardized quality crite-
ria to guide future attempts to manufacture
implantable myocardium.
Few studies, for instance, have reliably
and convincingly proved enhancement of
cardiac function after induction of myocar-
dial injury relative to control values. We
frequently see distorting scaffolds “sitting”
on the heart, or replacing previously beat-
ing muscle, and identify in most of the
cases significant foreign-body reaction and
reactive neovascularization3 interpreted as
angiogenesis. Frequently the immunologic
response to the implanted scaffold and the
inoculated cells is neglected, even when
species barriers are crossed. Furthermore,
many study designs fail to adhere to well-
described “hard problems” in the develop-
ment of bioartificial myocardium:
1. With respect to cardiac geometry, the
ventricular muscle constitutes a com-
plex helical structure.4 Symmetric
and isotropic matrices would pro-
mote scarring and aneurysm forma-
tion. The issues of asymmetry and
anisotropy of the heart have never
been addressed.
2. With respect to cardiac hemodynam-
ics, the modified law of Laplace for
the heart* defines circumferential
wall stress values that would not be
tolerated by most of the described
matrices. Very likely these matrices
would decompose, leading to severe
hemorrhage, or would form aneu-
rysms.
3. With respect to microscopic struc-
ture, we are unaware of approaches
that involve both including nerves
(conductive microstructures) and
preformed chaotic and plastic micro-
channnels simultaneously.
4. With respect to issues of storage,
conservation, and scale, an infant or
child with congenital defects will
*CWS  Pb/h  (1  b2/2a2  h/2b  h/8a2),
where: CWS is circumferential wall stress (in dyne/
cm2  103), P is left ventricular pressure (in dyne/
cm2), a and b are major and minor semiaxes, re-
spectively (in cm) and h is left ventricular wall
thickness (in cm).
Figure 1. Triple staining of carboxyfluorescein diacetate succinimidyl ester–labeled
cells in 3-dimensional scaffold consisting of collagen type 1. Nuclei stain blue. Red
“halo” marks myocytes (MF 20 stain). Here, cluster of cells aligns along fibers (longitu-
dinal structures at left encompassing the cells) of collagen network.
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